JUN and breast cancer: Considering that miR-137 is downregulated in many cancer tissues, including BCs, this novel p-c-Jun/miR-137-GSK3β-HSP70-MMP-2 axis would provide significant information to explore a potential therapeutic strategy for patients with invasive BC.